IND-SWIFT LABORATORIES LTD.

Ind-Swift Laboratories Ltd has announced that its Board of Directors will convene on October 29, 2026. The primary agenda for this meeting is to consider, approve, and take on record the standalone and consolidated un-audited financial results for the quarter and half-year ended September 30, 2026. The company has also reminded stakeholders about the previously communicated trading window closure details and the availability of this information on their corporate website.

Essix Biosciences Limited, along with other Persons Acting in Concert (PACs) from the Promoter and Promoter Group of Ind-Swift Laboratories Limited, has acquired 14,00,000 (14 Lakh) Equity Shares. This acquisition occurred on October 08, 2026, through the conversion of Fully Convertible Warrants. Following this transaction, the promoter group's holding in Ind-Swift Laboratories has changed. The total number of shares acquired is 14,00,000, representing 1.58% of the total diluted share capital. The total holding of Essix Biosciences Limited and PACs before the acquisition was 3,73,34,278 shares (42.93% of total capital), and after the acquisition, it stands at 3,87,34,278 shares (43.84% of total diluted capital).

Essix Biosciences Limited, part of the Promoter and Promoter Group of Ind-Swift Laboratories Limited, has acquired 14,00,000 equity shares. This acquisition occurred on October 8, 2026, through the conversion of Fully Convertible Warrants. The transaction represents a 1.58% increase in total shareholding for Essix Biosciences Limited, bringing their post-acquisition holding to 38.80% of the total capital. The total promoter and promoter group holding increased from 42.93% to 43.84%.

Ind-Swift Laboratories Limited announced the outcome of its Preferential Issue Committee Meeting held on October 8, 2026. The committee approved the allotment of 14,00,000 Equity Shares, face value ₹10 each, upon conversion of 14,00,000 Fully Convertible Warrants. These warrants were originally allotted on September 17, 2026, at an issue price of ₹196 per warrant. The conversion was made upon receipt of the balance 75% consideration of ₹147 per warrant, aggregating to ₹20,58,00,000 (₹20.58 Crore). The shares were allotted to Essix Biosciences Limited, part of the Promoter & Promoter Group. This allotment increases the company's paid-up equity share capital from ₹86,71,15,580 to ₹86,96,15,580.

Ind-Swift Laboratories Ltd has informed shareholders about SEBI's Master Circulars (May 07, 2024, and June 10, 2024) making it mandatory for physical share holders to update their PAN, KYC, and nomination details. Shareholders failing to update these details will not be eligible to lodge grievances or avail service requests from the Company’s RTA. Furthermore, from April 1, 2024, any payments, including dividends, interest, or redemption, will only be made through electronic mode upon complete furnishing of these details. The company has provided specific forms (ISR-1, ISR-2, SH-13, ISR-3, SH-14) and instructions for submitting these documents to their Registrar & Transfer Agent (RTA), Alankit Limited, via in-person verification, hard copy, or e-sign.

Ind-Swift Laboratories Ltd has announced the closure of its trading window for all promoters, directors, KMPs, designated persons, and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The window will remain shut from October 1, 2026, until 48 hours after the declaration of the un-audited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. This measure is standard practice to prevent potential insider trading activities around financial result announcements.

Essix Biosciences Limited, along with other promoter group members, has acquired 70,00,000 Fully Convertible Warrants in Ind-Swift Laboratories Limited on a preferential basis. These warrants are convertible into an equivalent number of equity shares. This acquisition, disclosed under SEBI's takeover regulations, signifies a strengthening of the promoter group's stake and potential future equity in the target company. The transaction occurred on September 17, 2026, with the disclosure made on September 21, 2026.

Essix Biosciences Limited, a promoter group entity of Ind-Swift Laboratories Ltd, has acquired 70,00,000 (Seventy Lakh) fully convertible warrants. These warrants, acquired for cash on a preferential basis on September 17, 2026, are convertible into an equivalent number of equity shares of face value ₹10 each. The disclosure was made under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The acquirer, along with other Persons Acting in Concert (PACs), belongs to the promoter and promoter group of Ind-Swift Laboratories Limited.

Ind-Swift Laboratories Ltd's Preferential Issue Committee has approved the allotment of 70,00,000 Fully Convertible Warrants to Essix Biosciences Limited, a promoter group entity. The warrants are issued at a price of Rs. 196/- each, with Rs. 49/- per warrant (25% of the issue price) received upfront, totaling Rs. 34.30 crore. This move is subject to prior shareholder and stock exchange approvals.

Ind-Swift Laboratories Ltd has announced its 31st Annual General Meeting (AGM) to be held on Wednesday, September 30, 2026, at 3:00 PM via Video Conferencing/Other Audio Visual Means. The company has fixed Wednesday, September 23, 2026, as the cut-off date for determining voting entitlements. The Register of Members and Share Transfer Books will remain closed from September 24, 2026, to September 30, 2026, inclusive, for the AGM. The Annual Report for FY 2025-26, detailing the company's transformation into a focused, debt-free formulation entity with global reach and robust R&D, is enclosed with the AGM notice. The company highlights its recent divestment of API and CRAMS business and merger into a single listed entity, positioning it for future growth funded by internal accruals.